Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Uptake In EU Could Slow If Innovators Switch Pricing Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Austerity has driven biosimilars in Europe, but IMS strategist cautions that further saving could be mercurial because of ancillary costs.

You may also be interested in...



How US Can Learn From Biosimilar Implementation In EU

Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.

Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven

EGA Director General Adrian van den Hoven will call on the new European Commission and Parliament to introduce efficiency policies to increase the uptake of and access to generic drugs and biosimilars.

European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals

Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel